Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 4/20 | 0.62 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.62 |
| ▸ | ICMT | O60725 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12520413 | 0.91 | MTNR1B (0.60) | MTNR1BMTNR1AICMTMEN1KMT2A | |
| SCHEMBL7745902 | 0.90 | MTNR1B (0.52) | MTNR1BMTNR1AICMTMEN1KMT2A | |
| SCHEMBL7505384 | 0.89 | MTNR1B (0.59) | MTNR1BMTNR1AICMTMEN1KMT2A | |
| SCHEMBL11114174 | 0.89 | MTNR1A (0.66) | MTNR1BMTNR1AICMTMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL7505379 | 0.88 | MTNR1B (0.57) | MTNR1BMTNR1AICMTMEN1KMT2A | |
| SCHEMBL11641239 | 0.88 | MTNR1B (0.57) | MTNR1BMTNR1AICMTMEN1KMT2A | |
| SCHEMBL5604615 | 0.88 | MTNR1B (0.57) | MTNR1BMTNR1AICMTMEN1KMT2A | |
| SCHEMBL7785497 | 0.88 | MTNR1B (0.51) | MTNR1BMTNR1AICMTMEN1KMT2A | |
| SCHEMBL42399 | 0.85 | MTNR1B (0.57) | MTNR1BMTNR1AMEN1KMT2AMAPT | |
| SCHEMBL38660132 | 0.85 | MTNR1B (0.57) | MTNR1BMTNR1AMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021257544-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2021-12-23 | — | — | WO | disclosed |
| WO-2021132245-A1 | METHOD FOR ASSISTING DIAGNOSIS OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER | 富士フイルム和光純薬株式会社 | 2021-07-01 | — | — | WO | disclosed |
| CN-107080747-A | Glucosylceramide synthase inhibitor | 建新公司 | 2017-08-22 | — | — | CN | disclosed |
| US-20160096819-A1 | PROCESS FOR PREPARING N-SUBSTITUTED 1H-PYRAZOLE-5-CARBOXYLIC ACID COMPOUNDS AND DERIVATIVES THEREOF | BASF SE (DE) | 2016-04-07 | — | — | US | disclosed |
| EP-2997020-A1 | PROCESS FOR PREPARING N-SUBSTITUTED 1H-PYRAZOLE-5-CARBOXYLIC ACID COMPOUNDS AND DERIVATIVES THEREOF | BASF SE (DE) | 2016-03-23 | — | — | EP | disclosed |
| WO-2014184343-A1 | PROCESS FOR PREPARING N-SUBSTITUTED 1H-PYRAZOLE-5-CARBOXYLIC ACID COMPOUNDS AND DERIVATIVES THEREOF | BASF SE (DE) | 2014-11-20 | — | — | WO | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-7868204-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2011-01-11 | — | — | US | disclosed |
| US-7838520-B2 | Inhibitors of histone deacetylase | METHYLGENE, INC. (CA) | 2010-11-23 | — | — | US | disclosed |
| US-7595343-B2 | Inhibitors of histone deacetylase | METHYLGENE, INC. (CA) | 2009-09-29 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-1420008-B1 | Composition, in particular cosmetic, comprising a secondary or tertiary amine | OREAL (FR) | 2006-12-20 | — | — | EP | disclosed |
| EP-1704161-A1 | HELIX 12 DIRECTED STEROIDAL PHARMACEUTICAL PRODUCTS | Endorecherche, Inc. (CA) | 2006-09-27 | — | — | EP | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| US-20050187211-A1 | N-arylsalkyl-carboxamide compositions and methods | WEI EDWARD T (US) | 2005-08-25 | — | — | US | disclosed |
| WO-2005066194-A1 | HELIX 12 DIRECTED STEROIDAL PHARMACEUTICAL PRODUCTS | ENDORECHERCHE, INC. (CA) | 2005-07-21 | — | — | WO | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
| EP-1420008-A1 | Composition, in particular cosmetic, comprising a secondary or tertiary amine | L'OREAL (FR) | 2004-05-19 | — | — | EP | disclosed |
| EP-0058868-A1 | Derivatives of tetrahydropyrimidinon, process for their preparation and herbicides containing those derivatives as active products | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1982-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187211-A1 | N-arylsalkyl-carboxamide compositions and methods | OPRL1, TRPV1, TRPA1 | MTNR1B 907/4885MTNR1A 788/4885ICMT 4765/4885 |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | MTNR1B 707/4885MTNR1A 802/4885ICMT 3305/4885 |
| US-20160096819-A1 | PROCESS FOR PREPARING N-SUBSTITUTED 1H-PYRAZOLE-5-CARBOXYLIC ACID COMPOUNDS AND DERIVATIVES THEREOF | CA3, CA2, CA1 | MTNR1B 2929/4885MTNR1A 2400/4885ICMT 882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.